KSKarel Willem Frank Scheepstra

Karel Willem Frank Scheepstra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Karel Willem Frank Scheepstra has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparing the Feasibility of In-Person and Online Preventive Cognitive Therapy for Major Depressive Disorder After Partial Response to Repetitive Transcranial Magnetic Stimulation: Protocol for a Pilot Randomized Controlled Trial

    by Ilke G S de Lange, Mariejean R C Albers, Karel W F Scheepstra, Claudi L Bockting, Laurien Aben

    Background: In recent years, repetitive transcranial magnetic stimulation (rTMS) has become a first-line recommendation in the Netherlands for individuals with major depressive disorder (MDD) who have not responded to a minimum of 2 prior treatments. Although rTMS can be effective, there is a significant risk of relapse after treatment. Currently, there are no standardized treatment options available after rTMS treatment completion aimed at preventing relapse. Preventive cognitive therapy (PCT) is a brief psychological intervention designed to prevent relapse in partially and fully remitted individuals with MDD. Objective: This study aims to establish the feasibility of 2 distinct forms of PCT (online and face-to-face) after intensive rTMS treatment for responding patients. Methods: Participants who demonstrate partial or full response to rTMS, defined as at least 25% reduction in symptoms, as quantified using the Inventory of Depressive Symptomatology–Self-Report (IDS-SR) or an IDS-SR score of 22 or lower will be included. Twenty participants will be randomly allocated to either face-to-face or online PCT, and treatment adherence will be compared between face-to-face and online treatment. The study will be deemed feasible if at least 75% of participants complete PCT during the grant duration of 1.5 years. For PCT, we aim to see which delivery format is the most feasible. Secondarily, changes in affective states, assessed through experience sampling data during PCT, will be studied to establish usefulness for a larger randomized controlled trial aimed at evaluating the effectiveness of PCT after rTMS. Finally, possible MDD relapse will be monitored throughout the intervention and follow-up periods. Results: This study was funded in November 2023 by the Netherlands Organisation for Health Research and Development. It was reviewed and approved according to the Medical Research Involving Human Subjects Act ( Wet Medisch-Wetenschappelijk Onderzoek met Mensen ) by the Medical Research Ethics Committee of Amsterdam University Medical Center on June 17, 2024. Data collection started in August 2024 and ended in April 2026, with an inclusion of 11 participants. As of June 2026, data analysis has not yet started. We expect data analysis and manuscript preparation of results to be completed in December 2026. Conclusions: If this pilot study shows preferred feasibility of a specific format of PCT (either online or face-to-face) following rTMS treatment for depression, a larger-scale randomized controlled clinical trial may be performed to study the effects of PCT on remission duration, relapse rates, and affective states in remitted individuals with MDD after rTMS treatment using this preferred delivery format. This pilot will provide insights into the feasibility of face-to-face or online PCT after successful rTMS treatment in depression.

  • Open Access

    A 3‐Month Follow‐Up Pilot Study on Accelerated Intermittent Theta Burst Stimulation for Bipolar Depression

    by Daan Neuteboom, Urmi Pahladsingh, Martijn C. Steinbach, Marjan C. Ploegaert, Jasper B. Zantvoord, Anja Lok, Lieuwe de Haan, Karel W. F. Scheepstra

    Background: Approximately 25% of patients with bipolar disorder are reported to have treatment‐resistant bipolar depression (TRBD). Accelerated intermittent Theta Burst Stimulation (aiTBS) is an innovative form of repetitive transcranial magnetic stimulation (rTMS), delivering bursts of stimulation at theta wave frequencies, which are believed to enhance synaptic plasticity. This pilot study aimed to explore the safety, tolerability, and preliminary efficacy of aiTBS in individuals with treatment‐resistant bipolar depression (TRBD). Methods: This open‐label pilot study (registered at Overview of Medical Research in the Netherlands (OMON), NL‐OMON53634), conducted between July 2023 and September 2024, included patients aged 43–64 years who were diagnosed with bipolar I or II and were experiencing a current moderate‐to‐severe depressive episode. Patients were required to have treatment‐refractory symptoms according to the Hidalgo‐Mazzei criteria. All patients were receiving antidepressant medication. Patients received eight daily sessions of intermittent Theta Burst Stimulation (iTBS) over five consecutive days, with 50‐min intervals between sessions. Stimulation targeted the left dorsolateral prefrontal cortex (DLPFC) using the BeamF3 targeting method. Outcomes included safety, tolerability, and efficacy and were assessed at day 3, day 5, week 2, week 4 and week 12 post‐treatment. Safety was assessed by documentation of serious adverse events (SAEs) and adverse events (AEs); tolerability was evaluated based on reported side effects. Efficacy was measured by the mean reduction in depression symptoms using the 17‐item Hamilton Depression Rating Scale (HDRS‐17). Results: Eight patients were recruited, all of whom completed the treatment course. aiTBS was well tolerated and no SAEs occurred during the treatment week or during follow‐up. The most frequently reported AEs were discomfort at the stimulation site and fatigue (87.5%). Although one patient experienced hypomanic symptoms (YMRS = 13) at the 3‐month follow‐up visit, this was considered unrelated to the study treatment due to the timing of onset, and because several significant psychosocial stressors were identified in the patient's life during that period. Mean HDRS scores decreased from 22.9 (SD = 4.4) at baseline to 16.6 (SD = 4.2) on day 3 of treatment (difference = 6.3 (95% CI, 1.6–10.9); 27.3% improvement, p = 0.01), 12.8 (SD = 4.1) on day 5 (difference = 10.1 (95% CI, 2.2–18.1); 44.3%, p = 0.02), 11.1 (SD = 3.8) at week 2 (difference = 11.8 (95% CI, 4.5–19.0); 51.4%, p = 0.004) and 13.5 (SD = 3.9) at week 4 (difference = 9.4 (95% CI, 1.0–17.7); 41.0% improvement, p = 0.03). At month 3, the mean HDRS score was 13.7 (SD = 6.9, difference compared to baseline = 9.1 (95% CI, −3.0 to 21.3); 40.0% improvement, p = 0.2). Conclusion: This pilot study extends prior evidence suggesting the antidepressant effects, safety, and tolerability of aiTBS in patients with TRBD; however, its durability may be limited. We recommend that future RCTs investigate relapse prevention following acute aiTBS and determine the optimal strategy for maintaining antidepressant effects.

  • Open Access

    Comparing in-person to online Preventive Cognitive Therapy (PCT) for major depressive disorder after repetitive transcranial magnetic stimulation (rTMS) response: Protocol of a Randomized Controlled Trial Pilot Study (Preprint)

    by Ilke G.S. de Lange, Mariejean R.C. Albers, Karel W.F. Scheepstra, Claudi L. Bockting, Laurien Aben

    BACKGROUND In recent years, repetitive Transcranial Magnetic Stimulation (rTMS) has become a first-line recommendation in the Netherlands for individuals with Major Depressive Disorder (MDD) who have not responded to a minimum of two prior treatments. Although rTMS can be effective, a significant risk of relapse exists after treatment. Currently, there are no standardized treatment options available post rTMS treatment completion aimed at preventing relapse. Preventive Cognitive Therapy (PCT) is a brief psychological intervention designed to prevent relapse in partially and fully remitted individuals of MDD. OBJECTIVE This study aims to establish feasibility of adding PCT after intensive rTMS treatment for responding patients. METHODS This pilot randomized controlled trial aims to investigate the feasibility of adding PCT following rTMS treatment for depression, either online or face-to-face. Participants who demonstrate partial or full response to rTMS, defined as at least 25% reduction in symptoms as quantified by the Inventory of Depressive Symptomatology - Self Rated (IDS-SR) or with IDS-SR score of 22 or lower will be included. Twenty participants will be randomly allocated to either face-to-face or online PCT treatment and treatment adherence between face to face or online treatment will be compared. Secondary, changes in affective states assessed through experience sampling data during PCT will be studied to establish usefulness for a larger RCT aimed on the effectiveness of PCT after rTMS. Lasty, possible relapse of MDD will be monitored throughout the intervention and follow-up period. RESULTS This study was reviewed and approved according to the Medical Research Involving Human Subjects Act (WMO; ‘Wet Medisch-Wetenschappelijk Onderzoek met Mensen’) by the Medical Research Ethics Committee of the Amsterdam UMC on 17th of June 2024 (trial register: NL85703.018.23). As of September 2025, participant recruitment has ended after 11 included participants. We expect data analysis and expected results to be published in fall 2026. CONCLUSIONS If this pilot study shows feasibility of adding PCT following rTMS treatment for depression either online of face-to-face, a larger-scale randomized controlled clinical trial may be performed to study the effects of PCT on remission durations, relapse rates and affective states in remitted MDD individuals after rTMS treatment. This pilot will provide insight into feasibility of face-to-face or online PCT treatment after successful rTMS treatment in depression. CLINICALTRIAL This trial has been registered in the Dutch national trial registry (Trial number: NL85703.018.23)

  • Open Access

    Comparison of 5-Day Multidaily Neuronavigated Theta-Burst Sessions With 6-Week Standard Repetitive Transcranial Magnetic Stimulation (the Dutch Depression Outcome Trial): Protocol for a Randomized Controlled Trial

    by Annemiek Dols, Tom Biemans, Coen Coomans, Philip van Eijndhoven, Iris Dalhuisen, Ysbrand D van der Werf, Chris Vriend, Elvira S Amaral Gomes, Alexander T Sack, Teresa Schuhmann, et al.

    Background: Novel therapies are crucial for patients with major depressive disorder, as more than 33% of patients do not respond to first-line treatments. A promising novel treatment strategy is an intensive 5-day course of personalized, functional connectivity–guided accelerated intermittent theta-burst stimulation (PAiT), modeled after the Stanford neuromodulation therapy protocol. This new form of repetitive transcranial magnetic stimulation (rTMS) may lead to higher remission rates in patients with treatment-resistant depression (TRD). However, it remains unclear how this accelerated strategy compares to the standard once-daily 10 Hz rTMS at inducing remission of depression. Objective: This study aims to compare cost-effectiveness using the PAiT protocol and the standard 10 Hz rTMS in patients with TRD. Methods: A total of 108 patients will be enrolled in this multicenter randomized controlled trial. Patients will receive stimulation over the left dorsolateral prefrontal cortex using either the PAiT protocol (10 sessions per day over 5 days, resulting in 50 sessions in total and 90,000 pulses) or standard 10 Hz rTMS (once daily for 6 weeks, resulting in 30 sessions in total and 90,000 pulses). Personalized targets will be identified in the accelerated intermittent theta-burst stimulation condition based on negative functional coupling between the subgenual anterior cingulate cortex and the dorsolateral prefrontal cortex. In the rTMS condition, the dorsolateral prefrontal cortex target locations are identified using the standard Beam-F3 method. In both conditions, coil placement is performed with neuronavigation, navigating either to the personalized functional connectivity target or the Beam-F3 location. Patients will undergo pre- and posttreatment functional magnetic resonance imaging scans, including cognitive and emotional tasks. Four follow-up assessments are scheduled at 7, 12, 26, and 31 weeks after baseline. We expect that the PAiT protocol is more cost-effective than the standard 10 Hz rTMS. Results: Recruitment for this randomized controlled trial started in February 2024. As of December 2024, we had enrolled 31 patients; the last participant is expected to complete their posttreatment assessments in January 2027. Conclusions: To our knowledge, this study is the first clinical trial to compare the cost- effectiveness of PAiT to standard 10 Hz rTMS as treatment for patients with TRD. The results of our study will offer professionals evidence from a sufficiently powered trial to determine whether the PAiT protocol is more effective than standard high-frequency rTMS. Specifically, it will assess whether PAiT leads to a shorter treatment duration for depression and greater societal or occupational participation among patients with TRD. In addition, this trial will provide further insights into the underlying mechanisms related to treatment effect, the effects of rTMS or accelerated intermittent theta-burst stimulation on cognitive domains such as executive functioning and emotion, possible differences in side effects, long-term effects, and factors contributing to possible relapse. Trial Registration: ClinicalTrials.gov NCT05900271; https://clinicaltrials.gov/study/NCT05900271 International Registered Report Identifier (IRRID): DERR1-10.2196/70121

  • Open Access

    A three-month follow-up pilot study on accelerated intermittent Theta Burst Stimulation for bipolar depression

    by Daan Neuteboom, Urmi Pahladsingh, Martijn C. Steinbach, Marjan C. Ploegaert, Jasper B. Zantvoord, Anja Lok, Lieuwe de Haan, Karel W.F. Scheepstra

    Background Approximately 25% of all patients with bipolar disorder are considered treatment-resistant. Accelerated intermittent Theta Burst Stimulation (aiTBS) is an innovative form of repetitive transcranial magnetic stimulation (rTMS), delivering bursts of stimulation at theta wave frequencies, which are believed to enhance synaptic plasticity. This pilot study aimed to explore the safety, tolerability, and preliminary efficacy of aiTBS in individuals with treatment-resistant bipolar depression (TRBD). Methods This open-label pilot study (Overview of Medical Research in the Netherlands (OMON): NL-OMON53634) included eight patients diagnosed with TRBD. Participants received eight daily sessions of intermittent Theta Burst Stimulation (iTBS) over five consecutive days, with 50-minute intervals between sessions. Stimulation targeted the left dorsolateral prefrontal cortex (dlPFC) using the BeamF3 targeting method. Primary outcomes were safety, tolerability, and efficacy. Safety was assessed by recording (serious) adverse events; tolerability was evaluated through side effect reports and dropout rates. Efficacy was measured as the mean reduction in depression severity, as assessed by the 17-item Hamilton Depression Rating Scale (HDRS-17). Results aiTBS was well tolerated and no SAEs occurred during the treatment week. Most observed adverse events were discomfort at the site of stimulation and fatigue [7/8, 87.5%]. No treatment-emergent [hypo]mania was observed during intervention week or during the follow-up. One patient experienced hypomanic symptoms [YMRS=13] at the 3 month follow-up visit. The mean HDRS decreased from 22.9 [SD=4.4] at baseline to 16.6 [SD=4.2] at day 3 of treatment [difference= -6.3 (95% CI, 1.6 – 10.9); 27.3% improvement, p=0.01*], decreased significantly to 12.3 [SD=4.1] at day 5 [difference= -10.1 (95% CI, 2.2 – 18.1); 44.3% improvement, p=0.02*], decreased significantly to 11.1 [SD=3.8] at week 2 of FU [difference= -11.8 (95% CI, 4.5 – 19.0); 51.4% improvement, p=0.004**] and decreased significantly to 13.5 [SD=3.9] at week 4 of FU [difference= -9.4 (95% CI, 1.0 – 17.7); 41.0% improvement, p=0.03*]. Conclusion This study extends on the previous of rapid antidepressant effects, safety and tolerability of aiTBS in patients with TRBD. We suggest future RCTs to investigate maintenance aiTBS or tapering studies, to possibly prolongate the antidepressant effect. Conflict of Interest declaration The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

  • Open Access

    Reporting Psychiatric Disease Characteristics in Post-Mortem- and Biological Research

    by Karel Scheepstra, Mark Mizee, Dennis Wever, Cheng-Chih Hsiao, Lin Zhang, Dick Swaab, Jörg Hamann, Inge Huitinga

    Inflammation is a prominent hypothesis in the neurobiology of depression. In our transcriptomic profiling study of microglia in chronic major depressive disorder (MDD), we revealed a distinct disease-associated microglia (DAM) transcriptomic profile exclusively found in cortical gray matter, that we have designated DepDAM. These DepDAM revealed an immune-suppressed state, with a possible upstream mechanism for microglial suppression, by upregulation of CD200 and CD47 (“don’t eat me signals”) located on synapses. We extensively report on disease characteristics, such as cause of death, reason for euthanasia, and psychiatric state when deceased. When excluding MDD donors in a euthymic state, the trend of lower CD45 membrane expression on white matter microglia became significant, and the difference in gray matter microglia became larger. For Western blot analysis of CD47 and CD200, both means of the definitely depressed donor groups (MDD-D) increased. This underscores the utmost importance of reporting on patient and episode characteristics, such as severity, episode traits, (type of) suicidality, mode of decease, and state of illness at death in post-mortem- and biological psychiatric research. For psychiatric post-mortem research, we suggest using well-characterized donors (eg, after “psychological autopsy”) selected by an experienced clinician.


  • Open Access

    A Multicenter Retrospective Chart Review on the Effectiveness and Tolerability of Electroconvulsive Therapy in Adolescents and Young Adults With Major Depressive Disorder or Bipolar Depression

    by Nout Schukking, Karel W.F. Scheepstra, Isidoor O. Bergfeld, Jeroen A. van Waarde, Indira Tendolkar, Harm-Pieter Spaans, Annette J. M. Hegeman, Dominique S. Scheepens, Anja Lok

    Background: Major depressive disorder and bipolar depression in adolescents and young adults are prevalent and major contributors to the global burden of disease, whereas effective interventions are limited. Available evidence is insufficient to assess effectiveness and tolerability of electroconvulsive therapy in depressed adolescents and young adults. Methods: A retrospective chart review was conducted in patients with major depressive disorder or bipolar depression who underwent electroconvulsive therapy from 2001 to 2021 in 12 centers in the Netherlands. Patients were classified as young (15–25 years) and older adults (26–80 years). Primary outcome was effectiveness, expressed as response (≥50% reduction in rating scale score compared with baseline) and remission. Rating scale scores were cross-sectionally assessed at baseline and at the end of the index course. Outcomes of remitters were included in responders. Secondary outcome was occurrence of subjective cognitive impairment and adverse events. Long-term outcomes were not available. Results: In the young (n = 57) and older adult (n = 41) group, 40.4% and 56.1% (P = 0.153) of patients achieved response and 28.1% and 39.0% (P = 0.281) remission, respectively. Subjective cognitive impairment (80.5% vs 56.3%; P = 0.001) and transient cardiac arrhythmia (14.6% vs 2.8%; P = 0.020) were reported significantly more frequently in the older adult group. Conclusions: Despite significantly more comorbidity of personality disorders, autism spectrum disorders, and anxiety disorders, effectiveness in the young was similar to the older adults. Tolerability was even superior in the young, despite significantly more bilateral treatment. Electroconvulsive therapy could be considered a viable treatment option in depressed adolescents and young adults.


  • Open Access

    Table of Contents

    by Raz Yirmiya, Sara Poletti, Matteo Carminati, Raffaella Zanardi, Juan Belforte, Yoel Green, Yaakov Green, Bernice Yau, David Early, Graziano Pinna, et al.

  • Open Access

    Accelerated intermittent theta burst stimulation in major depressive disorder: A systematic review

    by Daan Neuteboom, Jasper B. Zantvoord, Roberto Goya-Maldonado, Jonas Wilkening, Annemieke Dols, Eric van Exel, Anja Lok, Lieuwe de Haan, Karel W.F. Scheepstra


  • Open Access

    Microglia Transcriptional Profiling in Major Depressive Disorder Shows Inhibition of Cortical Gray Matter Microglia

    by Karel W.F. Scheepstra, Mark R. Mizee, Jackelien van Scheppingen, Adelia Adelia, Dennis D. Wever, Matthew R.J. Mason, Marissa L. Dubbelaar, Cheng-Chih Hsiao, Bart J.L. Eggen, Jörg Hamann, et al.